keyword
MENU ▼
Read by QxMD icon Read
search

Psoriatic arthritis

keyword
https://www.readbyqxmd.com/read/28338619/role-and-function-of-a2a-and-a%C3%A2-adenosine-receptors-in-patients-with-ankylosing-spondylitis-psoriatic-arthritis-and-rheumatoid-arthritis
#1
Annalisa Ravani, Fabrizio Vincenzi, Alessandra Bortoluzzi, Melissa Padovan, Silvia Pasquini, Stefania Gessi, Stefania Merighi, Pier Andrea Borea, Marcello Govoni, Katia Varani
Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are chronic inflammatory rheumatic diseases that affect joints, causing debilitating pain and disability. Adenosine receptors (ARs) play a key role in the mechanism of inflammation, and the activation of A2A and A₃AR subtypes is often associated with a reduction of the inflammatory status. The aim of this study was to investigate the involvement of ARs in patients suffering from early-RA (ERA), RA, AS and PsA. Messenger RNA (mRNA) analysis and saturation binding experiments indicated an upregulation of A2A and A₃ARs in lymphocytes obtained from patients when compared with healthy subjects...
March 24, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28331299/assessing-physician-and-patient-acceptance-of-infliximab-biosimilars-in-rheumatoid-arthritis-ankylosing-spondyloarthritis-and-psoriatic-arthritis-across-germany
#2
John Waller, Emma Sullivan, James Piercy, Christopher M Black, Sumesh Kachroo
OBJECTIVES: We examined rheumatologists' motivation for prescribing biosimilars, assessed their treatment preferences in relation to prescribing behavior and explored patient attitudes to biosimilars. METHODS: Data were taken from the Adelphi Real World Biosimilars Programme, a real-world, cross-sectional study undertaken with German rheumatologists and patients with rheumatoid arthritis, ankylosing spondyloarthritis or psoriatic arthritis in 2015-2016. Rheumatologists provided data on their prescribing behavior and attitudes toward biosimilars and invited the next eight eligible consecutive consulting patients to complete a questionnaire...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28329487/apremilast-for-the-treatment-of-psoriatic-arthritis
#3
Brent C Martin, Logan W Thomas, Francis J Dann
Psoriatic arthritis (PsA) is a chronic inflammatoryarthropathy that affects joints and entheses andis associated with psoriasis (PsO). There are fiveclinical patterns of PsA: symmetrical polyarthritis,distal interphalangeal arthropathy, asymmetricaloligoarthritis, arthritis mutilans, and spondylitis, withor without sacroiliitis. Concerning PsA, the goals oftherapy are to control inflammation, prevent articulardamage, and reduce discomfort in the affected joints.Although there are many therapeutic options forthe treatment of PsAs, physicians most often beginwith nonsteroidal anti-inflammatory drugs (NSAIDs)for mild disease...
February 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28320454/mitigation-of-disease-and-treatment-related-risks-in-patients-with-psoriatic-arthritis
#4
REVIEW
Martin Bergman, Amy Lundholm
Psoriatic arthritis is a part of the family of diseases referred to as spondyloarthropathies, a diverse group of chronic inflammatory disorders with common clinical, radiographic, and genetic features. Peripheral arthritis is the most common symptom of psoriatic arthritis and patients also frequently experience involvement of the entheses, spine, skin, and nails. Due to the diverse clinical spectrum of disease severity, tissues affected, and associated comorbidities, the treatment of psoriatic arthritis can be challenging and it is necessary to mitigate risks associated with both the disease and its treatment...
March 20, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28320213/rethinking-costs-of-psoriasis-10-of-patients-account-for-nearly-40-of-healthcare-expenditures-among-enrollees-with-psoriasis-in-a-u-s-health-plan
#5
April W Armstrong, Yang Zhao, Vivian Herrera, Yunfeng Li, Tim Bancroft, Michael Hull, Aylin Altan
OBJECTIVE: To examine characteristics, healthcare utilization and costs among patients with psoriasis who have high medical costs. METHODS: This is a retrospective study of patients with psoriasis with continuous enrollment from 1 January 2011 to 31 December 2013 in a large US health plan. Total paid 2012 healthcare costs excluding biologics (to identify costliest not due to biologic costs) were used to create cohorts representing the top 10% (T10) and bottom 90% (B90) of expenditures...
March 20, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28319620/clinical-pearl-early-diagnosis-of-nail-psoriasis-and-psoriatic-arthritis
#6
Shari R Lipner, Matilde Iorizzo
No abstract text is available yet for this article.
February 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28319617/biosimilars-in-psoriasis-the-future-or-not
#7
Roselyn Kellen, Gary Goldenberg
As patents for the biologic agents reach their expiration dates, dermatologists must prepare for the coming of biosimilars. These agents have been deemed "highly similar" to their reference products in a process outlined by the US Food and Drug Administration (FDA). In 2016, the FDA approved 3 biosimilars for various indications including plaque psoriasis and psoriatic arthritis. However, biosimilars are not the same as small-molecule generics because they have a complex manufacturing process that makes it impossible to produce identical products to their reference products...
February 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28319289/clinical-characteristics-of-psoriasis-in-inflammatory-bowel-diseases-patients
#8
L Pescitelli, M Gianotta, F Ricceri, L Lazzeri, M Milla, F Prignano
Crohn's Disease (CD) and Ulcerative Colitis (UC) account for most cases of Inflammatory Bowel Diseases (IBD). These diseases share common genetic abnormalities and pathogenic mechanisms with other immune-mediated diseases including Psoriasis (Pso) [1, 2]. A recent study investigating specifics Pso characteristics in IBD patients (phenotype, severity) revealed that in IBD patients the frequency of plaque-type Pso, nail Pso, Psoriatic Arthritis and severe Pso seems to be lower compared with non-IBD patients [3]...
March 20, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28314685/association-of-psoriasis-and-psoriatic-arthritis-with-osteoporosis-and-pathological-fractures
#9
Parul Kathuria, Kenneth B Gordon, Jonathan I Silverberg
BACKGROUND: Previous studies examining the relationship between psoriasis (Pso), osteoporosis, and pathological fractures found conflicting results. OBJECTIVE: To determine whether Pso and psoriatic arthritis (PsA) are associated with osteoporosis and fractures in US adults. METHODS: Cross-sectional study of 198,102,435 children and adults, including 183,725 with Pso and 28,765 with PsA from the 2006-2012 National Emergency Department Sample, including 20% of the emergency care visits throughout the United States...
March 14, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28303758/beneficial-effect-of-n-3-polyunsaturated-fatty-acids-on-inflammation-and-analgesic-use-in-psoriatic-arthritis-a-randomized-double-blind-placebo-controlled-trial
#10
S Kristensen, E B Schmidt, A Schlemmer, C Rasmussen, M B Johansen, J H Christensen
OBJECTIVE: This study aimed to investigate the effects of marine n-3 polyunsaturated fatty acids (PUFAs) on disease activity, use of analgesics, and inflammatory biomarkers in patients with psoriatic arthritis (PsA). METHOD: Patients with established PsA (n = 145) were investigated in a randomized, double-blind, placebo-controlled study. The participants received a supplement of 3 g n-3 PUFA/day or 3 g olive oil/day (control) for 24 weeks. Outcome measures for disease activity, use of analgesics, and leukotriene formation from activated granulocytes were assessed at baseline and at study end...
March 17, 2017: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/28300300/patient-education-and-screening-for-psoriatic-arthritis-is-key-in-the-care-of-patients-with-psoriasis-whichever-method-is-chosen
#11
L C Coates
No abstract text is available yet for this article.
March 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28293452/prevalence-of-metabolic-syndrome-and-degree-of-cardiovascular-disease-risk-in-patients-with-psoriatic-arthritis
#12
Sıdıka Gülkan Özkan, Hatice Yazısız, Ahmet Behlül, Yüksel Aslı Gökbelen, Fatih Borlu, Veli Yazısız
OBJECTIVE: The aim of this study was to identify the prevalence of metabolic syndrome (MetS) and degree of cardiovascular disease (CVD) risk in patients with psoriatic arthritis (PsA). MATERIAL AND METHODS: We performed a cross-sectional study on 102 adult patients with PsA and a control group of 102 patients with rheumatoid arthritis (RA). MetS was diagnosed according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) and International Diabetes Federation (IDF) criteria...
March 2017: European Journal of Rheumatology
https://www.readbyqxmd.com/read/28293449/subclinical-enthesopathy-in-patients-with-psoriasis-and-its-association-with-other-disease-parameters-a-power-doppler-ultrasonographic-study
#13
Abdelhafeez Moshrif, Ahmed Mosallam, Essam Elden M Mohamed, Wesam Gouda, Mostafa Doma
OBJECTIVE: This study aimed to determine the prevalence of subclinical enthesopathy in patients with psoriasis using power Doppler ultrasonography (PDUS) and its association with other disease parameters. MATERIAL AND METHODS: A total of 50 patients with psoriasis (31 females) aged 19-70 years underwent a thorough clinical examination that included assessment of body mass index (BMI) and psoriasis area and severity index (PASI) score. Measurements of inflammatory markers, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), serum uric acid, and plain radiography of the heels, knees, and sacroiliac joints were performed for all patients...
March 2017: European Journal of Rheumatology
https://www.readbyqxmd.com/read/28293446/real-life-experience-of-using-conventional-disease-modifying-anti-rheumatic-drugs-dmards-in-psoriatic-arthritis-psa-retrospective-analysis-of-the-efficacy-of-methotrexate-sulfasalazine-and-leflunomide-in-psa-in-comparison-to-spondyloarthritides-other-than-psa
#14
Euthalia Roussou, Aicha Bouraoui
OBJECTIVE: With the aim of assessing the response to treatment with conventional disease-modifying anti-rheumatic drugs (DMARDs) used in patients with psoriatic arthritis (PsA), data on methotrexate, sulfasalazine (SSZ), and leflunomide were analyzed from baseline and subsequent follow-up (FU) questionnaires completed by patients with either PsA or other spondyloarthritides (SpAs). MATERIAL AND METHODS: A single-center real-life retrospective analysis was performed by obtaining clinical data via questionnaires administered before and after treatment...
March 2017: European Journal of Rheumatology
https://www.readbyqxmd.com/read/28290979/orbital-cellulitis-in-a-psoriatic-patient-treated-with-adalimumab
#15
Vienna G Katana, Robert J Carpenter, John P Trafeli, Julia M Kwan
INTRODUCTION: Psoriatic patients on tumor necrosis factor alpha inhibitors (TNFi) may be at increased risk for upper respiratory tract infections, including chronic rhino-sinusitis (CRS). Rarely, CRS can progress to orbital cellulitis (OC), an emergent ophthalmic complication wherein respiratory flora from paranasal sinus disease intrude the retro-orbital space. MATERIALS AND METHODS: Single case report. RESULTS: We report the first case, to our knowledge, of an invasive sinusitis that rapidly evolved into OC in a patient receiving adalimumab treatment for plaque psoriasis and psoriatic arthritis...
March 2017: Military Medicine
https://www.readbyqxmd.com/read/28288790/establishment-of-the-first-who-international-standard-for-etanercept-a-tnf-receptor-ii-fc-fusion-protein-report-of-an-international-collaborative-study
#16
Meenu Wadhwa, Chris Bird, Paula Dilger, Peter Rigsby, Haiyan Jia, Marie Emmanuelle Behr Gross
Etanercept, a recombinant human tumor necrosis factor (TNF) receptor Fc fusion protein is an effective treatment option in adults with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis and paediatrics with juvenile idiotypic arthritis and plaque psoriasis. Patent expiration in Europe and intense development of various etanercept products worldwide triggered a need for an international reference standard to facilitate determination of biological activity. Therefore, three candidate preparations of etanercept were lyophilized and evaluated in a multi-centre collaborative study comprising twenty eight laboratories from 15 countries for their suitability to serve as an international standard for the bioactivity of TNF receptor II Fc fusion proteins (international nonproprietary name, Etanercept)...
March 10, 2017: Journal of Immunological Methods
https://www.readbyqxmd.com/read/28284772/development-of-a-checklist-for-patients-with-axial-spondyloarthritis-and-psoriatic-arthritis-in-daily-practice-only-tools-project
#17
Raquel Almodovar, Juan C Torre Alonso, Enrique Batlle, Concepción Castillo, Eduardo Collantes-Estevez, Eugenio de Miguel, Senén González, Jordi Gratacós, Azucena Hernández, Xavier Juanola, Luis F Linares, Manuel J Moreno, Mireia Moreno, Victoria Navarro-Compán, Carlos Rodríguez Lozano, Jesus Sanz, Agustí Sellas, Estíbaliz Loza, Pedro Zarco
OBJECTIVE: To standardize clinical evaluation of patients with axial spondyloarthritis (SpA) and psoriatic arthritis (PsA) using a checklist. METHODS: Qualitative study that included: 1) nominal group (18 experts); 2) literature reviews of measures used in the assessment of patients with axial SpA or PsA; and 3) focus groups, one with rheumatologists and another with patients, organized to become familiar with their opinion on medical assistance. Taking this into account, the experts selected the measures to be included in the checklist based on their relevance, feasibility, and the outcome type...
March 8, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/28281458/biologic-treatment-for-rheumatic-disease-real-world-big-data-analysis-from-the-greek-country-wide-prescription-database
#18
Petros P Sfikakis, Vasiliki-Kalliopi Bournia, Prodromos Sidiropoulos, Dimitrios T Boumpas, Alexandros A Drosos, George D Kitas, George Konstantonis, Stamatis N Liossis, Menelaos N Manoussakis, Lazaros Sakkas, Maria Tektonidou, Athanasios G Tzioufas, Panayiotis G Vlachoyiannopoulos, Chara Kani, Panayiotis Paterakis, Panayiota Litsa, Dimitrios Vassilopoulos
OBJECTIVES: To directly assess the prevalence of inflammatory rheumatic disease under treatment with biologic disease modifying anti-rheumatic drugs (b-DMARDs) and compare treatment patterns between rheumatoid arthritis (RA) and spondyloarthropathy (SpA), including psoriatic arthritis. METHODS: The obligatory country-wide prescription electronic database covering 10.223.000 Greek citizens (95.1% of the population, 99.5% Caucasian), all of whom with fully reinbursed access to b-DMARDs, was used to retrospectively capture all patients under b-DMARDs for RA/SpA between June 2014-May 2015...
March 3, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28280401/review-of-the-treatment-of-psoriatic-arthritis-with-biological-agents-choice-of-drug-for-initial-therapy-and-switch-therapy-for-non-responders
#19
REVIEW
Salvatore D'Angelo, Giuseppina Tramontano, Michele Gilio, Pietro Leccese, Ignazio Olivieri
Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease with a broad clinical spectrum and variable course. It can involve musculoskeletal structures as well as skin, nails, eyes, and gut. The management of PsA has changed tremendously in the last decade, thanks to an earlier diagnosis, an advancement in pharmacological therapies, and a wider application of a multidisciplinary approach. The commercialization of tumor necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab) as well as interleukin (IL)-12/23 (ustekinumab) and IL-17 (secukinumab) inhibitors is representative of a revolution in the treatment of PsA...
2017: Open Access Rheumatology: Research and Reviews
https://www.readbyqxmd.com/read/28279855/anti-therapeutic-antibodies-and-their-clinical-impact-in-patients-treated-with-the-tnf-antagonist-adalimumab
#20
Isabelle Cludts, Francesca Romana Spinelli, Francesca Morello, Jason Hockley, Guido Valesini, Meenu Wadhwa
Patients treated with the TNF antagonist adalimumab develop anti-therapeutic antibodies (ATA), the prevalence of which varies depending on the assay used. Most assays are compromised due to the presence of adalimumab in the clinical samples. Our objective was to develop an antibody assay, applicable for clinical testing, which overcomes the limitation of therapeutic interference and to further determine the relationship between ATA development, adalimumab levels and disease activity in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS)...
March 6, 2017: Cytokine
keyword
keyword
135
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"